BCR and leukemia: The BCR::ABL1 fusion oncoprotein, which has tyrosine kinase activity (Cetin et al., 2021) and activates different downstream signal pathways, such as JAK-STAT, MAPK/ERK, and PI3K/Akt/mTOR, promotes the occurrence and development of leukemia (Singh et al., 2021).